← Patent-cliff monitor small molecule SPINRAZA NUSINERSEN SODIUM
Loss of exclusivity December 2030 latest FDA-listed patent expiry
Company Biogen → See this company's full patent-cliff portfolio Drug detail Brand name SPINRAZA Active ingredient NUSINERSEN SODIUM Strength EQ 28MG BASE/5ML (EQ 5.6MG BASE/ML) Dosage form SOLUTION Route INTRATHECAL Modality Small molecule FDA approval March 2026 Marketing status RX
Listed patents Patent Expires Type 8361977 December 2030 substance, product 8980853 November 2030 use U-1941 9717750 June 2030 use U-1942 7838657 July 2027 substance, product
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.